Jump to content

Cachexia

From Wikipedia, the free encyclopedia
(Redirected from Cancer cachexia)
"Wasting syndrome" redirects here. For the process by which a debilitating disease causes muscle and fat tissue to "waste" away, see wasting.

Cachexia
Other namesWasting syndrome
Person with cancer-associated cachexia
SpecialtyOncology, Internal Medicine, Physical Medicine and Rehabilitation
Symptomssudden weight loss, altered eating signals
Prognosisvery poor
Frequency1%
Deaths1.5 to 2 million people a year

Cachexia (/kəˈkɛksiə/[1]) is a syndrome that happens when people have certain illnesses, causing muscle loss that cannot be fully reversed with improved nutrition.[2] It is most common in diseases like cancer, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, and AIDS.[3][4] These conditions change how the body handles inflammation, metabolism, and brain signaling, leading to muscle loss and other harmful changes to body composition over time.[5] Unlike weight loss from not eating enough, cachexia mainly effects muscle and can happen with or without fat loss.[6] Diagnosis of cachexia is difficult because there are no clear guidelines, and its occurrence varies from one affected person to the next.[7]

Like malnutrition, cachexia can lead to worse health outcomes and lower quality of life.[8][9][10]

Definition

[edit]

Cachexia is hard to define because it often happens alongside malnutrition and sarcopenia.[11] Since there are no clear rules separating these conditions, experts continue working to agree on definitions to help treat these nutrition-related problems.

In the past, cachexia was described as "a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass."[9] In 2011, experts updated this definition, saying cachexia is "a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment."[2] They also suggested breaking it into three stages: pre-cachexia, cachexia, and refractory cachexia.[2]

Cachexia and Malnutrition

[edit]

Cachexia and malnutrition are related but not the same. Malnutrition happens when the body doesn't get enough nutrients, leading to changes in body weight, physical strength, and mental function.[3][4] Malnutrition includes both disease-related malnutrition as well as malnutrition without disease such as seen in starvation or aging.[3] Cachexia should be viewed as a type of malnutrition in which inflammation from a long-term illness causes unwanted muscle loss. [3]

Cachexia and Sarcopenia

[edit]

Cachexia and sarcopenia are similar because both cause weight and muscle loss, along with symptoms like weakness and loss of appetite.[12] The difference is sarcopenia is caused by aging, while cachexia happens due to long-term disease and inflammation.[11][12]

Causes

[edit]

Cachexia is most commonly associated end-stage cancer, often called cancer cachexia.[13]

Other conditions that frequently cause cachexia include:

Cachexia can happen in late stages of diseases like cystic fibrosis, multiple sclerosis, motor neuron disease, Parkinson's disease, dementia, tuberculosis, multiple system atrophy, mercury poisoning, Crohn's disease, trypanosomiasis, rheumatoid arthritis,celiac disease, and other diseases that effect the entire body.[15][16]

Mechanism

[edit]
Processes and mechanisms related to cancer-associated cachexia

The way cachexia works is not well understood, but research suggests it is linked to inflammation, changes in metabolism, and hormone changes in the body .[5]

Inflammatory

[edit]

Certain molecules in the body, called Inflammatory cytokines, play a big role in causing cachexia. Two important ones are tumor necrosis factor (TNF) and interleukin 6 (IL-6).[6]

Tumor Necrosis Factor (TNF)

[edit]

TNF breaks down muscle and fat while stopping new muscle and fat cells from forming by activating the ubiquitin proteasome pathway.[5][6][17][18][19][20] It also triggers the release of other cytokines that also speed up muscle loss. Since this process is very complex, cachexia is unlikely to be caused by one molecule.[18]While it is thought to be produced by immune cells called macrophages, scientists are still unsure of exactly where TNF is produced in cachexia.[6]

Interleukin-6 (IL-6)

[edit]

IL-6 is thought to cause muscle loss by starting a pathway called the JAK/STAT pathway.[5][6][20][21] IL-6 is produced by immune cells called macrophages, potentially producing acute phase reactants which may worsen muscle loss.[6][18]

Other molecules may include:

  • Myostatin - Prevents muscle growth and is often higher in people with cancer.[6][18][22]
  • Activin - May contribute to muscle loss when TNF is also active.[6][18]
  • Growth Differentiation Factor 15 (GDF-15) - Normally produced during cellular stress. Thought to play a role in food aversion and is associated with reduced food intake.[5]

Metabolic

[edit]

Cachexia can also result from changes in metabolism. Tumors sometimes release molecules that break down fat and muscle, causing cachexia by making it harder for the body to keep up with energy needs.[19] These molecules include lipid mobilizing factor, proteolysis-inducing factor, and mitochondrial uncoupling proteins.[19][23] In addition, uncontrolled inflammation in people with cachexia increases the body's need for nutrients.[20][22]

The way the body uses nutrients is also changed in cachexia. People with cachexia can have loss of appetite, are less responsive to insulin, and can have increased fat breakdown, all of which make it difficult for the body to properly use food. This is especially true in people with cancer.[18]

Hormonal

[edit]

Hormones are signaling molecules used to regulate bodily behavior and are believed to play a role in cachexia as well.

Glucocorticoids are produced as part of the body's natural response to stress. They are also known to play a role in muscle breakdown.[6][24] Furthermore, people with long-term illness such as cancer are frequently treated with glucocorticoids, making cachexia more likely in these individuals.[6]

Some tumors produce a molecule called parathyroid-related peptide (PTHrP). It increases metabolism by stimulating energy production in the mitochondria of fat cells.[18][19][20]

Leptin is a hormone known to decrease appetite. People with cachexia often have high leptin levels, making them feel less hungry.[19]

The hypothalamus, the brain's appetite control center, is also affected in cachexia. Given the hypothalamic function in controlling appetite, it is believed to play a role in cachexia.[5] The appetite-controlling center of the hypothalamus is controlled by neuropeptide Y (NPY) and agouti gene-related protein (AgRP) that increase appetite, as well as proopiomelanocortin (POMC) and cocaine and amphetamine-regulated transcrip (CART) that decrease appetite.[19][20] Inflammation may disrupt these appetite signals, causing reduced hunger and leading to further weight and muscle loss. However, scientists are still studying exactly how this process works.[18][19][20]

Diagnosis

[edit]

Previous Criteria for Diagnosing Cachexia

[edit]

Doctors used to diagnose cachexia mainly by looking at changes in body weight. A person was considered to have cachexia if they had a low BMI or unwanted weight loss of more than 10%.[25] However, only using weight is not always a reliable method. Factors like fluid buildup (edema), tumor size, and obesity can make it difficult to diagnose cachexia.[25] These weight-based criteria do not account for muscle loss, which is a key part in cachexia. .[25]

To improve diagnosis of cachexia, experts proposed adding lab tests and symptom evaluations.[9] With that, a person might have cachexia if they lost at least 5% of their in 12 months or had a BMI under less 22 kg/m2 with at least three of the following: weak muscles, fatigue, loss of appetite, low muscle mass, or abnormal labs.[9]

There have also been attempts to define specific types of cachexia, such as cardiac cachexia, which can occur in people with congestive heart failure.[26] However, there is no widely accepted definition for it.[26]

Current Criteria for Diagnosing Cachexia

[edit]

Cancer cachexia is now diagnosed based on:

  1. Unwanted weight loss of more than 5% within 6 months.[2][19]
  2. For people with a BMI of less than 20kg/m2, weight loss of more than 2%.[2][19][27]
  3. For people with sarcopenia, weight loss of more than 2%.[2][19][27]

New ways to score and stage cachexia are being explored, particularly in people with advanced cancer.[19]

Scoring systems for Cachexia

[edit]

To better understand how bad cachexia is in each person, doctors now use scoring systems like the Cachexia Staging Score and Cachexia Score.[19]

The Cachexia Staging Score (CSS) looks at weight loss, muscle function, appetite loss, and lab test results to categorize people into four stages: non-cachexia, pre-cachexia, cachexia, and refractory cachexia.[25] Those in more advanced stages have less muscle mass, more frequent age-related muscle loss, worse symptoms, poorer quality of life, as well as shorter survival periods.[19]

Staging

[edit]
  • Non-cachexia (0-2 points) - No major weight loss or problems with appetite.[19]
  • Pre-cachexia (3-4 points) - Mild weight loss and appetite issues. Early treatment at this stage might slow progression of cachexia.[19]
  • Cachexia (5-8 points) - Significant muscle loss that is difficult to reverse and affects daily function.[28]
  • Refractory cachexia (9-12 points) - Severe weight and muscle loss with poor response to treatment and a life expectancy of less than 3 months.[19]


The Cachexia SCOre (CASCO) is another scoring system that looks at weight loss, inflammation, metabolism, immune function, physical ability, appetite, and quality of life to provide a more detailed assessment.[25]

Laboratory Tests for Cachexia

[edit]

Laboratory tests are sometimes used to check for cachexia. Tests that are used include albumin, C-reactive protein, ghrelin, IGF-2, and leptin.[7] Acute phase reactants (IL-6, IL-1b, tumor necrosis factor, IL-8, interferon gamma and serum cytokines are also studied but are not always reliable for predicting cachexia.[7][18] Laboratory cut-off values are also not the same across different institutions.[7] There is no single lab test that can confirm cachexia or predict who will develop it.[11][25]

Imaging

[edit]

One challenge in diagnosing cachexia is measuring muscle loss in an easy and affordable way. Some imaging techniques that can help assess body composition include:

However, these methods are not widely used because they can be expensive and difficult to access.[25]

Treatment

[edit]

Because cachexia is a complex condition with several potential causes, treatment requires multiple approaches at the same time.[7] The best strategy is to treat the cause of the cachexia, if known.[5][29] For example, people with cachexia caused by AIDS often improve after starting treatment for AIDS.[30] However, because the exact mechanism of cachexia is unclear, there is no single medication that can effectively treat it.[20] Instead, treatment focuses on a combination of exercise, nutrition, medications, and psychosocial support.[20]

Exercise

[edit]

Regular physical exercise is recommended for the treatment of cachexia because of its positive effects on muscle function.[20] Exercise can reduce protein breakdown, improve muscle strength, decrease inflammation, and enhance metabolism.[20] However, its effectiveness in cancer patients - especially those who are frail or have sarcopenia - remains uncertain.[20][31] Many people with cachexia also avoid exercise because they lack motivation or fear that it will worsen their symptoms.[32]

Nutrition

[edit]

Cachexia can increase metabolism and suppress appetite, worsening the present muscle loss.[22] Studies show that high-calorie, protein-rich diets may help stabilize weight, though they do not necessarily improve muscle mass.[17] Current recommendations include 1.5g/kg/day of protein, making up 15-20% of daily calories.[20] However, feeding tubes (enteral nutrition) should not be used routinely.[33]

Medications

[edit]

Some medications, such as glucocorticoids, cannabinoids, and progestins were initially used in treating cachexia and aim to increase appetite.[20] Progestins showed promise initially, but they do not stop muscle wasting and may cause fluid retention, fat gain, and other side effects.[7][11][20][34]

Ghrelin agonists, such as Anamorelin are commonly used in cancer treatment to boost appetite, increase weight, and increase muscle mass.[20] However, its use and effectiveness in cachexia is not well studied.

Selective androgen receptor modulators (SARMs) such as Enobosarm show promise in increasing physical performance and muscle mass, but more studies are needed to confirm their effectiveness in cachexia.[7]

The use of anti-inflammatory medications have been investigated. Thalidomide, an anti-inflammatory agent, has shown promise in preventing weight loss, but the use of this medication in cachexia is not widely accepted.[7][35] However, other TNF inhibitors have not shown the same promising results.[20] NSAIDs such as celecoxib and ibuprofen showed some early benefits, but side effects (renal injury, GI bleeding) limit their use.[7]

Anti-nausea drugs such as 5-HT3 antagonists are also commonly used if nausea is a prominent symptom.[17]

Anabolic steroids like oxandrolone may help but are only recommended for short term use due to side effects including liver toxicity.[7][34][36]

Supplements

[edit]

The use of certain amino acids may slow muscle breakdown by providing the body with the building blocks needed for metabolism of muscle and glucose. Specifically, leucine and valine may block muscle breakdown.[37] Glutamine is used in oral supplements for people with advanced cancer[38] or HIV/AIDS.[39]

β-hydroxy β-methylbutyrate (HMB) is a molecule that comes from leucine that promotes muscle growth. Studies show positive results for chronic pulmonary disease, hip fracture, and in AIDS-related and cancer-related cachexia. However, it is often studied along with other nutrients, making it difficult to assess its effects alone.[40][41]

Creatine supplementation may help reduce muscle wasting, though more research is needed.[42]

Epidemiology

[edit]

Accurate epidemiological data on the prevalence of cachexia is lacking due to changing diagnostic criteria and under-identification of people with the disorder.[43] It is estimated that cachexia from any disease is estimated to affect more than 5 million people in the United States.[11] The prevalence of cachexia is growing and estimated at 1% of the population. The prevalence is lower in Asia but due to the larger population, represents a similar burden. Cachexia is also a significant problem in South America and Africa.[43]

Within people with cancer, prevalence of cachexia was previously reported to range from 11%-71%.[44] Recent updates show that 33%-51.8% of people with cancer develop cachexia, though current estimates of prevalence vary widely and may be unreliable due to absence of consensus guidelines for diagnosis, variability in cancer populations, and variability in timing of diagnosis.[11][45][46] Specifically, the highest rates were seen in older populations as well as those with upper gastrointestinal, colorectal, and lung cancers, respectively.[11][46] The prevalence increases in advanced cancer stages, affecting up to 80% of terminal cancer cases.[13]

The most frequent diseases causing cachexia in the United States are: 1) Cancer , 2) chronic heart failure, 3) chronic kidney disease, 4) COPD.[43]

Cachexia contributes to significant loss of function and healthcare utilization. Estimates suggest that cachexia accounted for 177,640 hospital stays in 2016 in the United States.[47] Cachexia is considered the immediate cause of death of many people with cancer, estimated between 22 and 40%.[48]

History

[edit]

The word "cachexia" is derived from the Greek words "Kakos" (bad) and "hexis" (condition). English ophthalmologist John Zachariah Laurence was the first to use the phrase "cancerous cachexia", doing so in 1858. He applied the phrase to the chronic wasting associated with malignancy. It was not until 2011 that the term "cancer-associated cachexia" was given a formal definition, with a publication by Kenneth Fearon. Fearon defined it as "a multifactorial syndrome characterized by ongoing loss of skeletal muscle (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment".[27]

Research

[edit]

Several medications are under investigation or have been previously trialed for use in cachexia but are currently not in widespread clinical use:

Medical marijuana has been allowed for the treatment of cachexia in some US states, such as Missouri, Illinois, Maryland, Delaware, Nevada, Michigan, Washington, Oregon, California, Colorado, New Mexico, Arizona, Vermont, New Jersey, Rhode Island, Maine, and New York [52][53] Hawaii[54] and Connecticut.[55][56]

Multimodal therapy

[edit]

Despite the extensive investigation into single therapeutic targets for cachexia, the most effective treatments use multi-targeted therapies. In Europe, a combination of non-drug approaches including physical training, nutritional counseling, and psychotherapeutic intervention are used in belief this approach may be more effective than monotherapy.[34] Administration of anti-inflammatory drugs showed efficacy and safety in the treatment of people with advanced cancer cachexia.[49]

See also

[edit]

References

[edit]
  1. ^ "Cachexia | Definition of Cachexia by Lexico". Lexico Dictionaries | English. Archived from the original on 8 November 2019.
  2. ^ a b c d e f Fearon K, Strasser F, Anker SD, et al. (May 2011). "Definition and classification of cancer cachexia: an international consensus". The Lancet Oncology. 12 (5): 489–95. doi:10.1016/s1470-2045(10)70218-7. PMID 21296615.{{cite journal}}: CS1 maint: overridden setting (link)
  3. ^ a b c d Cederholm T, Barazzoni R, Austin P, et al. (2017). "ESPEN guidelines on definitions and terminology of clinical nutrition". Clinical Nutrition. 36 (1): 49–64. doi:10.1016/j.clnu.2016.09.004. hdl:11368/2883964. PMID 27642056.
  4. ^ a b Muscaritoli M, Anker S, Argilés J, et al. (2009). "Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics"". Clinical Nutrition. 29 (2): 154–159. doi:10.1016/j.clnu.2009.12.004. PMID 20060626.
  5. ^ a b c d e f g Ferrer M, Anthony TG, Ayres JS, et al. (2023). "Cachexia: A systemic consequence of progressive, unresolved disease". Cell. 186 (9): 1824–1845. doi:10.1016/j.cell.2023.03.028. PMC 11059056. PMID 37116469.
  6. ^ a b c d e f g h i j Fearon KC, Glass DJ, Guttridge DC (August 2012). "Cancer Cachexia: Mediators, Signaling, and Metabolic Pathways". Cell Metabolism. 16 (2): 153–166. doi:10.1016/j.cmet.2012.06.011. PMID 22795476.
  7. ^ a b c d e f g h i j Sadeghi M, Keshavarz-Fathi M, Baracos V, et al. (1 July 2018). "Cancer cachexia: Diagnosis, assessment, and treatment". Critical Reviews in Oncology/Hematology. 127: 91–104. doi:10.1016/j.critrevonc.2018.05.006. ISSN 1040-8428.
  8. ^ Norman K, Pichard C, Lochs H, et al. (2008). "Prognostic impact of disease-related malnutrition". Clinical Nutrition. 27 (1): 5–15. doi:10.1016/j.clnu.2007.10.007. PMID 18061312.
  9. ^ a b c d Evans WJ, Morley JE, Argilés J, et al. (December 2008). "Cachexia: a new definition". Clinical Nutrition. 27 (6): 793–9. doi:10.1016/j.clnu.2008.06.013. PMID 18718696. S2CID 206821612.{{cite journal}}: CS1 maint: overridden setting (link)
  10. ^ Bossi P, Delrio P, Mascheroni A, et al. (9 June 2021). "The Spectrum of Malnutrition/Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review". Nutrients. 13 (6): 1980. doi:10.3390/nu13061980. ISSN 2072-6643. PMC 8226689. PMID 34207529.
  11. ^ a b c d e f g Peterson SJ, Mozer M (February 2017). "Differentiating Sarcopenia and Cachexia Among Patients With Cancer". Nutrition in Clinical Practice. 32 (1): 30–39. doi:10.1177/0884533616680354. PMID 28124947. S2CID 206555460.
  12. ^ a b Meza-Valderrama D, Marco E, Dávalos-Yerovi V, et al. (26 February 2021). "Sarcopenia, Malnutrition, and Cachexia: Adapting Definitions and Terminology of Nutritional Disorders in Older People with Cancer". Nutrients. 13 (3): 761. doi:10.3390/nu13030761. ISSN 2072-6643. PMC 7996854. PMID 33652812.
  13. ^ a b Fearon KC, Moses AG (September 2002). "Cancer cachexia". International Journal of Cardiology. 85 (1): 73–81. doi:10.1016/S0167-5273(02)00235-8. PMID 12163211.
  14. ^ a b c d Ebner N, Springer J, Kalantar-Zadeh K, et al. (July 2013). "Mechanism and novel therapeutic approaches to wasting in chronic disease". Maturitas. 75 (3): 199–206. doi:10.1016/j.maturitas.2013.03.014. PMID 23664695. S2CID 42148927.[permanent dead link‍]
  15. ^ Meresse B, Ripoche J, Heyman M, et al. (January 2009). "Celiac disease: from oral tolerance to intestinal inflammation, autoimmunity and lymphomagenesis". Mucosal Immunology. 2 (1): 8–23. doi:10.1038/mi.2008.75. PMID 19079330. S2CID 24980464.
  16. ^ Morley JE, Thomas DR, Wilson MM (April 2006). "Cachexia: pathophysiology and clinical relevance". The American Journal of Clinical Nutrition. 83 (4): 735–43. doi:10.1093/ajcn/83.4.735. PMID 16600922.
  17. ^ a b c Kumar NB, Kazi A, Smith T, et al. (December 2010). "Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment". Current Treatment Options in Oncology. 11 (3–4): 107–17. doi:10.1007/s11864-010-0127-z. PMC 3016925. PMID 21128029.
  18. ^ a b c d e f g h i Petruzzelli M, Wagner EF (1 March 2016). "Mechanisms of metabolic dysfunction in cancer-associated cachexia". Genes & Development. 30 (5): 489–501. doi:10.1101/gad.276733.115. ISSN 0890-9369. PMC 4782044. PMID 26944676.
  19. ^ a b c d e f g h i j k l m n o p Nishikawa H, Goto M, Fukunishi S, et al. (6 August 2021). "Cancer Cachexia: Its Mechanism and Clinical Significance". International Journal of Molecular Sciences. 22 (16): 8491. doi:10.3390/ijms22168491. ISSN 1422-0067. PMC 8395185. PMID 34445197.
  20. ^ a b c d e f g h i j k l m n o p Setiawan T, Sari IN, Wijaya YT, et al. (22 May 2023). "Cancer cachexia: molecular mechanisms and treatment strategies". Journal of Hematology & Oncology. 16 (1): 54. doi:10.1186/s13045-023-01454-0. ISSN 1756-8722. PMC 10204324. PMID 37217930.
  21. ^ Moresi V, Adamo S, Berghella L (30 April 2019). "The JAK/STAT Pathway in Skeletal Muscle Pathophysiology". Frontiers in Physiology. 10: 500. doi:10.3389/fphys.2019.00500. ISSN 1664-042X. PMC 6502894. PMID 31114509.
  22. ^ a b c Argilés JM, Campos N, Lopez-Pedrosa JM, et al. (September 2016). "Skeletal Muscle Regulates Metabolism via Interorgan Crosstalk: Roles in Health and Disease". Journal of the American Medical Directors Association. 17 (9): 789–96. doi:10.1016/j.jamda.2016.04.019. PMID 27324808.
  23. ^ Martignoni ME, Kunze P, Friess H (November 2003). "Cancer cachexia". Molecular Cancer. 2 (1): 36. doi:10.1186/1476-4598-2-36. PMC 280692. PMID 14613583.
  24. ^ Salehian B, Kejriwal K (1999). "Glucocorticoid-Induced Muscle Atrophy: Mechanisms And Therapeutic Strategies". Endocrine Practice. 5 (5): 277–281. doi:10.4158/EP.5.5.277. PMID 15251668.
  25. ^ a b c d e f g Dev R (January 2019). "Measuring cachexia-diagnostic criteria". Annals of Palliative Medicine. 8 (1): 24–32. doi:10.21037/apm.2018.08.07. PMID 30525765.
  26. ^ a b Anker SD, Coats AJ (1999). "Cardiac Cachexia". Chest. 115 (3): 836–847. doi:10.1378/chest.115.3.836. PMID 10084500.
  27. ^ a b c Biswas AK, Acharyya S (2020). "Cancer-Associated Cachexia: A Systemic Consequence of Cancer Progression". Annual Review of Cancer Biology. 4: 391–411. doi:10.1146/annurev-cancerbio-030419-033642.
  28. ^ Arends J, Baracos V, Bertz H, et al. (October 2017). "ESPEN expert group recommendations for action against cancer-related malnutrition". Clinical Nutrition. 36 (5): 1187–1196. doi:10.1016/j.clnu.2017.06.017.
  29. ^ "Care Management Guidelines Fatigue, Anorexia and Cachexia" (PDF). Archived from the original (PDF) on 14 May 2014. Retrieved 23 February 2014.
  30. ^ "AIDS Wasting Syndrome". WebMD.
  31. ^ Grande AJ, Silva V, Sawaris Neto L, et al. (March 2021). "Exercise for cancer cachexia in adults". The Cochrane Database of Systematic Reviews. 2021 (3): CD010804. doi:10.1002/14651858.CD010804.pub3. PMC 8094916. PMID 33735441.
  32. ^ Wasley D, Gale N, Roberts S, et al. (February 2018). "Patients with established cancer cachexia lack the motivation and self-efficacy to undertake regular structured exercise" (PDF). Psycho-Oncology. 27 (2): 458–464. doi:10.1002/pon.4512. hdl:10369/8759. PMID 28758698. S2CID 206378678.
  33. ^ Roeland EJ, Bohlke K, Baracos VE, et al. (20 July 2020). "Management of Cancer Cachexia: ASCO Guideline". Journal of Clinical Oncology. 38 (21): 2438–2453. doi:10.1200/JCO.20.00611. ISSN 0732-183X.
  34. ^ a b c d e f g h "New European Guidelines: Clinical Practice Guidelines on Cancer Cachexia in Advanced Cancer Patients". European Palliative Care Research Collaborative. Archived from the original on 2 May 2014. Retrieved 23 February 2014.
  35. ^ Reid J, Mills M, Cantwell M, et al. (April 2012). "Thalidomide for managing cancer cachexia". The Cochrane Database of Systematic Reviews. 2021 (4): CD008664. doi:10.1002/14651858.cd008664.pub2. PMC 6353113. PMID 22513961.
  36. ^ Giovanni Mantovani (6 October 2007). Cachexia and Wasting: A Modern Approach. Springer Science & Business Media. pp. 673–. ISBN 978-88-470-0552-5.
  37. ^ Eley HL, Russell ST, Tisdale MJ (October 2007). "Effect of branched-chain amino acids on muscle atrophy in cancer cachexia". The Biochemical Journal. 407 (1): 113–20. doi:10.1042/BJ20070651. PMC 2267397. PMID 17623010.
  38. ^ May PE, Barber A, D'Olimpio JT, et al. (April 2002). "Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine". American Journal of Surgery. 183 (4): 471–9. doi:10.1016/s0002-9610(02)00823-1. PMID 11975938.
  39. ^ "Glutamine". WebMD. WebMD, LLC. Retrieved 15 March 2015.
  40. ^ Brioche T, Pagano AF, Py G, et al. (August 2016). "Muscle wasting and aging: Experimental models, fatty infiltrations, and prevention" (PDF). Molecular Aspects of Medicine. 50: 56–87. doi:10.1016/j.mam.2016.04.006. PMID 27106402. S2CID 29717535.
  41. ^ Holeček M (August 2017). "Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions". Journal of Cachexia, Sarcopenia and Muscle. 8 (4): 529–541. doi:10.1002/jcsm.12208. PMC 5566641. PMID 28493406.
  42. ^ Lulu W, Ranran W, Kai L, et al. (7 December 2022). "Creatine modulates cellular energy metabolism and protects against cancer cachexia-associated muscle wasting". Frontiers in Pharmacology. 13. doi:10.3389/fphar.2022.1086662. PMC 9767983. PMID 36569317.
  43. ^ a b c von Haehling S, Anker SD (September 2010). "Cachexia as a major underestimated and unmet medical need: facts and numbers". Journal of Cachexia, Sarcopenia and Muscle. 1 (1): 1–5. doi:10.1007/s13539-010-0002-6. PMC 3060651. PMID 21475699.
  44. ^ Anker MS, Holcomb R, Muscaritoli M, et al. (2019). "Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review". Journal of Cachexia, Sarcopenia and Muscle. 10 (1): 22–34. doi:10.1002/jcsm.12402. ISSN 2190-5991. PMC 6438416. PMID 30920776.
  45. ^ Takaoka T, Yaegashi A, Watanabe D (2024). "Prevalence of and Survival with Cachexia among Patients with Cancer: A Systematic Review and Meta-Analysis". Advances in Nutrition. 15 (9): 100282. doi:10.1016/j.advnut.2024.100282. PMC 11402144. PMID 39127425.
  46. ^ a b Poisson J, Martinez-Tapia C, Heitz D, et al. (2021). "Prevalence and prognostic impact of cachexia among older people with cancer: a nationwide cross-sectional survey (NutriAgeCancer)". Journal of Cachexia, Sarcopenia and Muscle. 12 (6): 1477–1488. doi:10.1002/jcsm.12776. ISSN 2190-5991. PMC 8718093. PMID 34519440.
  47. ^ Barrett ML, Bailey MK, Owens PL. Non-maternal and Non-neonatal Inpatient Stays in the United States Involving Malnutrition, 2016. ONLINE. August 30, 2018. U.S. Agency for Healthcare Research and Quality. Available: https://www.hcup-us.ahrq.gov/reports/HCUPMalnutritionHospReport_083018.pdf Archived 2021-11-27 at the Wayback Machine.
  48. ^ Alhamarneh O, Agada F, Madden L, et al. (March 2011). "Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma". Head & Neck. 33 (3): 415–23. doi:10.1002/hed.21464. PMID 20645289. S2CID 20061488.
  49. ^ a b Argilés JM, Busquets S, López-Soriano FJ (September 2011). "Anti-inflammatory therapies in cancer cachexia". European Journal of Pharmacology. 668 (Suppl 1): S81–6. doi:10.1016/j.ejphar.2011.07.007. PMID 21835173.
  50. ^ Ries A, Trottenberg P, Elsner F, et al. (June 2012). "A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project" (PDF). Palliative Medicine. 26 (4): 294–304. doi:10.1177/0269216311418709. PMID 21865295. S2CID 2801425.
  51. ^ a b Suzuki H, Asakawa A, Amitani H, et al. (May 2013). "Cancer cachexia--pathophysiology and management". Journal of Gastroenterology. 48 (5): 574–94. doi:10.1007/s00535-013-0787-0. PMC 3698426. PMID 23512346.
  52. ^ "Program Information and News - New York State Medical Marijuana Program". www.health.ny.gov.
  53. ^ Rules Governing the Maine Medical Use of Marijuana Program Archived 2014-11-12 at the Wayback Machine - 10-144 CMR Chapter 122 - Section 3.1.3
  54. ^ "Medical Marijuana Registry Program | Eligible Debilitating Medical Conditions". health.hawaii.gov. Archived from the original on 22 May 2016. Retrieved 27 April 2016.
  55. ^ Gagnon B, Bruera E (May 1998). "A review of the drug treatment of cachexia associated with cancer". Drugs. 55 (5): 675–88. doi:10.2165/00003495-199855050-00005. PMID 9585863. S2CID 22180434.
  56. ^ Yavuzsen T, Davis MP, Walsh D, et al. (November 2005). "Systematic review of the treatment of cancer-associated anorexia and weight loss". Journal of Clinical Oncology. 23 (33): 8500–11. doi:10.1200/JCO.2005.01.8010. PMID 16293879.
[edit]
Look up cachexia in Wiktionary, the free dictionary.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cachexia&oldid=1272910411"